



218306

00-000000000

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at . Please contact CVS/Caremark at 1-888-413-2723 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

| Patient Name: Patient ID: Patient Group No: | | | _ Date: Patient Date Of Birth: | | Physician Name: Specialty: Physician Office Telephone: | | | | |
|---|--|--|--|-------|--|---|--|--|--|
| | | NPI#: | Patient Phone: | Spe | | | | | |
| Phy | ysician Office Address: | | | | | | | | |
| Dru | ıg Name (specify drug) | | | | | | | | |
| Quantity: Route of Administration: Diagnosis: | | | <u>_</u> | ngth: | | | | | |
| | | | Expected Length of Therapy: ICD Code: | | | | | | |
| | mments: | | | | | | | | |
| | | | | | | | | | |
| 1. | What is the diagnosis? | e answer for each applicat | • | | | | | | |
| | Pulmonary arterial hypertension (PAH) (If checked, go to 3) | | | | | | | | |
| | Secondary Raynaud's phenomenon (If checked, go to 4) | | | | | | | | |
| | Erectile dysfunction (If checked, go to 2) | | | | Ш | | | | |
| | Other, please specify. | . (If checked, no further quest | tions) | | | | | | |
| 2. | erectile dysfunction. Bas coverage as it is not being current plan approved of and strength for pulmona phenomenon. If you wou | sed on your response, this reing prescribed for a diagnosis riteria. Current plan approved ary arterial hypertension (PA uld like to proceed, select Yes II require additional clinical re | eing requested for a diagnosis of quest is not likely to be approved for that is covered under the patient's dicriteria will only approve this drugh) and secondary Raynaud's sidelow. Submission of this prior view. If you would like not to proce | | | | | | |
| | Yes (If checked, no fu | rther questions) | | | | | | | |
| | No - Please cancel re | quest. (If checked, no further | questions) | | | | | | |
| 3. | Is the requested drug pr | escribed by or in consultation | n with a pulmonologist or cardiolog | st? Y | | N | | | |
| 4. | Is the patient currently re | eceiving treatment with the re | equested drug? | Υ | | N | | | |
| 5. | Is the patient currently rebenefit? | eceiving the requested drug t | hrough a paid pharmacy or medica | I | | | | | |
| | Yes (If checked, go to | 6) | | | | | | | |
| | No (If checked, go to | 7) | | | | | | | |
| | Unknown (If checked, | go to 7) | | | | | | | |
| 6. | Is the patient experiencing disease stability or disease | ng benefit from therapy with tase improvement? | the requested drug as evidenced b | у ү | | N | | | |
| 7. | What is the diagnosis? | | | | | | | | |
| | Pulmonary arterial hy | pertension (PAH) (If checked | l. ao to 8) | | | | | | |

| Γ | | | | | |
|-----|---|---|---|---|--|
| | Secondary Raynaud's phenomenon (If checked, go to 17) | | | | |
| 8. | What is the World Health Organization (WHO) classification of pulmonary hypertension? | | | | |
| | WHO Group 1 (Pulmonary arterial hypertension) (If checked, go to 9) | | | | |
| | WHO Group 2 (Pulmonary hypertension due to left heart disease) (If checked, no further questions) | | | | |
| | WHO Group 3 (Pulmonary hypertension due to lung disease and/or hypoxia) (If checked, no further questions) | | | | |
| | WHO Group 4 (Pulmonary hypertension due to pulmonary artery obstruction) (If checked, no further questions) | | | | |
| | WHO Group 5 (Pulmonary hypertension with unclear and/or multifactorial mechanisms) (If checked, no further questions) | | | | |
| 9. | Has the diagnosis been confirmed by pretreatment right heart catheterization? | Υ | | N | |
| 10. | What is the pretreatment mean pulmonary arterial pressure (mPAP)? | | | | |
| | Greater than 20 mmHg (If checked, go to 11) | | | | |
| | Less than or equal to 20 mmHg (If checked, no further questions) | | | | |
| 11. | What is the pretreatment pulmonary capillary wedge pressure (PCWP)? | | | | |
| | Less than or equal to 15 mmHg (If checked, go to 12) | | | | |
| | Greater than 15 mmHg (If checked, no further questions) | | | | |
| 12. | Is the patient less than 18 years of age? | Y | | N | |
| 13. | What is the pretreatment pulmonary vascular resistance (PVR)? | | | | |
| | Greater than or equal to 3 Wood units (If checked, no further questions) | | | | |
| | Less than 3 Wood units (If checked, no further questions) | | | | |
| 14. | What is the pretreatment pulmonary vascular resistance index (PVRI)? (Note: m2 represents unit of body surface area, meters squared.) | | | | |
| | Greater than or equal to 3 Wood units x m2 (If checked, no further questions) | | | | |
| | Less than 3 Wood units x m2 (If checked, no further questions) | | | | |
| 15. | Is the patient an infant less than one year of age? | Y | | N | |
| 16. | Has Doppler echocardiogram been performed to confirm the diagnosis? | Υ | | N | |
| 17. | Has the patient had an inadequate response to one of the following drugs: A) Calcium channel blockers, B) Angiotensin II receptor blockers, C) Selective serotonin reuptake inhibitors, D) Alpha blockers, E) Angiotensin-converting enzyme inhibitors, or F) Topical nitrates? | | | | |
| | Yes - Calcium channel blockers (If checked, no further questions) | | | | |
| | Yes - Angiotensin II receptor blockers (If checked, no further questions) | | | | |
| | Yes - Selective serotonin reuptake inhibitors (If checked, no further questions) | | | | |
| | Yes - Alpha blockers (If checked, no further questions) | | П | | |
| | Yes - Angiotensin-converting enzyme inhibitors (If checked, no further questions) | | | | |
| | Yes - Topical nitrates (If checked, no further questions) | | | | |
| | No - Other, please specify. (If checked, no further questions) | | | | |
| | Taris, produce opening, (in chestical, the failure questions) | | | | |

Γ

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date

Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.